Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STAT3 | P40763 | 1/20 | 0.41 |
| ▸ | STAT1 | P42224 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29430977 | 0.97 | STAT3 (0.42) | STAT3STAT1 | |
| SCHEMBL15809 | 0.97 | STAT3 (0.42) | STAT3STAT1 | |
| SCHEMBL6517023 | 0.97 | STAT3 (0.42) | STAT3STAT1 | |
| SCHEMBL30821407 | 0.97 | STAT3 (0.42) | STAT3STAT1 | |
| SCHEMBL6744970 | 0.97 | STAT3 (0.42) | STAT3STAT1 | |
| SCHEMBL9430673 | 0.97 | STAT3 (0.42) | STAT3STAT1 | |
| SCHEMBL1572838 | 0.95 | STAT3 (0.41) | STAT3STAT1 | |
| SCHEMBL5069984 | 0.95 | STAT3 (0.41) | STAT3STAT1 | |
| SCHEMBL705768 | 0.95 | STAT3 (0.41) | STAT3STAT1 | |
| Bromide SCHEMBL11339396 | 0.95 | STAT3 (0.41) | STAT3STAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11078220-B2 | High-purity large-scale preparation of stannsoporfin | Mallinckrodt Hospital Products IP Limited (IE) | 2021-08-03 | — | — | US | disclosed |
| US-20200255458-A1 | HIGH-PURITY LARGE-SCALE PREPARATION OF STANNSOPORFIN | MALLINCKRODT LLC | 2020-08-13 | — | — | US | disclosed |
| US-10662209-B2 | High-purity large-scale preparation of stannsoporfin | Mallinckrodt Hospital Products IP Limited (IE) | 2020-05-26 | — | — | US | disclosed |
| US-20190202846-A1 | HIGH-PURITY LARGE-SCALE PREPARATION OF STANNSOPORFIN | SpecGx LLC | 2019-07-04 | — | — | US | disclosed |
| US-10273255-B2 | High-purity large-scale preparation of stannsoporfin | INFACARE PHARMACEUTICAL CORPORATION (US) | 2019-04-30 | — | — | US | disclosed |
| CN-104116745-B | composition comprising stannsoporfin | 婴儿护理药品公司 | 2018-07-06 | — | — | CN | disclosed |
| US-20180134735-A1 | HIGH-PURITY LARGE-SCALE PREPARATION OF STANNSOPORFIN | MALLINCKRODT LLC | 2018-05-17 | — | — | US | disclosed |
| US-9902745-B2 | High-purity large-scale preparation of stannsoporfin | INFACARE PHARMACEUTICAL CORPORATION (US) | 2018-02-27 | — | — | US | disclosed |
| US-20170073362-A1 | HIGH-PURITY LARGE-SCALE PREPARATION OF STANNSOPORFIN | VTESSE LLC | 2017-03-16 | — | — | US | disclosed |
| US-9517239-B2 | High-purity large-scale preparation of stannsoporfin | INFACARE PHARMACEUTICAL CORPORATION (US) | 2016-12-13 | — | — | US | disclosed |
| US-8835416-B2 | High-purity large-scale preparation of stannsoporfin | INFACARE PHARMACEUTICAL CORPORATION (US) | 2014-09-16 | — | — | US | disclosed |
| US-20140005380-A1 | HIGH-PURITY LARGE-SCALE PREPARATION OF STANNSOPORFIN | INFACARE PHARMACEUTICAL CORPORATION (US) | 2014-01-02 | — | — | US | disclosed |
| US-8530458-B2 | High-purity large-scale preparation of stannsoporfin | INFACARE PHARMACEUTICAL CORPORATION (US) | 2013-09-10 | — | — | US | disclosed |
| EP-2384756-A2 | High-purity large-scale preparation of stannsoporfin | InfaCare Pharmaceutical Corporation (US) | 2011-11-09 | — | — | EP | disclosed |
| US-7960371-B2 | reduction of hemin with hydrogenation catalysts, in the presence of hydrogen, then heating to remove iron and form mesoporphyrin, and reacting with tin oxide top form pure tin mesoporphyrin; inhibitor of heme oxygenase, used in the treatment of infant jaundice or hyperbilirubinemia; liver disorders | INFACARE PHARMACEUTICAL CORPORATION (US) | 2011-06-14 | — | — | US | disclosed |
| US-20110082292-A1 | HIGH-PURITY LARGE-SCALE PREPARATION OF STANNSOPORFIN | OCERA THERAPEUTICS LLC | 2011-04-07 | — | — | US | disclosed |
| CN-101573122-A | High purity large scale preparation of stannsoporfin | INFACARE PHARMACEUTICAL CORP (US) | 2009-11-04 | — | — | CN | disclosed |
| EP-2079472-A2 | HIGH-PURITY LARGE-SCALE PREPARATION OF STANNSOPORFIN | InfaCare Pharmaceutical Corporation (US) | 2009-07-22 | — | — | EP | disclosed |
| US-20080125585-A1 | HIGH-PURITY LARGE-SCALE PREPARATION OF STANNSOPORFIN | STRATATECH CORPORATION | 2008-05-29 | — | — | US | disclosed |
| WO-2008045377-A2 | HIGH-PURITY LARGE-SCALE PREPARATION OF STANNSOPORFIN | INFACARE PHARMACEUTICAL CORPORATION (US) | 2008-04-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140005380-A1 | HIGH-PURITY LARGE-SCALE PREPARATION OF STANNSOPORFIN | SNRPF, HNRNPF, NUP188 | STAT3 4852/4885STAT1 4523/4885 |
| US-20180134735-A1 | HIGH-PURITY LARGE-SCALE PREPARATION OF STANNSOPORFIN | SNRPF, HNRNPF, NUP188 | STAT3 4852/4885STAT1 4523/4885 |
| US-10662209-B2 | High-purity large-scale preparation of stannsoporfin | SNRPF, HNRNPF, NUP188 | STAT3 4852/4885STAT1 4523/4885 |
| US-20080125585-A1 | HIGH-PURITY LARGE-SCALE PREPARATION OF STANNSOPORFIN | SNRPF, HNRNPF, NUP188 | STAT3 4852/4885STAT1 4523/4885 |
| US-10273255-B2 | High-purity large-scale preparation of stannsoporfin | SNRPF, HNRNPF, NUP188 | STAT3 4852/4885STAT1 4523/4885 |
| US-20200255458-A1 | HIGH-PURITY LARGE-SCALE PREPARATION OF STANNSOPORFIN | SNRPF, HNRNPF, NUP188 | STAT3 4852/4885STAT1 4523/4885 |
| US-20170073362-A1 | HIGH-PURITY LARGE-SCALE PREPARATION OF STANNSOPORFIN | SNRPF, HNRNPF, NUP188 | STAT3 4852/4885STAT1 4523/4885 |
| US-11078220-B2 | High-purity large-scale preparation of stannsoporfin | SNRPF, HNRNPF, NUP188 | STAT3 4852/4885STAT1 4523/4885 |
| US-20190202846-A1 | HIGH-PURITY LARGE-SCALE PREPARATION OF STANNSOPORFIN | SNRPF, HNRNPF, NUP188 | STAT3 4852/4885STAT1 4523/4885 |
| US-20110082292-A1 | HIGH-PURITY LARGE-SCALE PREPARATION OF STANNSOPORFIN | SNRPF, HNRNPF, NUP188 | STAT3 4852/4885STAT1 4523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.